Daiichi Eyes First-Line AML Filings For Vanflyta On Positive Data
Overcoming Past Later-Line Setbacks?
Daiichi Sankyo is aiming to overcome past US and EU setbacks for its FLT3 inhibitor Vanflyta with planned filings for first-line AML on the back of positive new Phase III data.
You may also be interested in...
The sponsors of Alsitek and quizartinib are hoping that new data generated for the drugs will resolve the concerns raised by the European Medicines Agency when it previously rejected the products for marketing in the EU.
The main Japanese pharma players report a generally strong fiscal Q1, helped by mainstays including Daiichi Sankyo's Enhertu, Astellas's Xtandi and Padcev and Chugai's Actemra, and in some cases by the weaker yen.
Japanese company Daiichi Sankyo has its eye on first-line FLT3-ITD AML indication after rejection of relapsed/refractory plans in EU and US.